Related references
Note: Only part of the references are listed.A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2013)
B-cell biology and development
Kathrin Pieper et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Paul F. Robbins et al.
NATURE MEDICINE (2013)
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H. Vonderheide et al.
ONCOIMMUNOLOGY (2013)
A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
Anna K. Nowak et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors
Jens Rueter et al.
CANCER BIOLOGY & THERAPY (2010)
Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
Erica L. Carpenter et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H. Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prospect of targeting the CD40 pathway for cancer therapy
Robert H. Vonderheide
CLINICAL CANCER RESEARCH (2007)
Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial F-18-FDG PET scans
Roslyn J. Francis et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
B cells as antigen presenting cells
D Rodríguez-Pinto
CELLULAR IMMUNOLOGY (2005)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
JP van Meerbeeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
MJ Byrne et al.
ANNALS OF ONCOLOGY (2004)
Soluble CD40 ligand in pulmonary arterial hypertension -: Possible pathogenic role of the interaction between platelets and endothelial cells
JK Damås et al.
CIRCULATION (2004)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
